Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
1 hedge funds and large institutions have $0 invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
100% less capital invested
Capital invested by funds: $1 → $0 (-$1)
Top Buyers
Top Sellers
DNA.WS Hedge Fund Activity: Q1 2026 in Review
1 of the 8,198 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q1 2026, worth a combined $0 — down 100% from $1 a quarter earlier.
Fund positioning in DNA.WS was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
- 1 institutional investor held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $0 of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q1 2026 and 0 closed out.
Based on aggregated 13F filings for Q1 2026.